Monitoring metal-amyloid-β complexation by a FRET-based probe: design, detection, and inhibitor screening This work reports the development and utilization of a probe capable of monitoring metal-amyloid-β (Aβ) complexation based on Förster resonance energy transfer (FRET). The probe, composed of Aβ1-21 grafted with a pair of FRET donor and acceptor, is able to provide a FRET signal upon Zn(II) binding even at nanomolar concentrations. Moreover, the probe is demonstrated to be used for screening a chemical library to identify eff ective inhibitors against Aβ aggregation due to metal-Aβ interaction.
Introduction
The number of aged people affected by neurodegenerative diseases has been increasing; however, the development of treatments for the diseases has not been successful due to the lack of understanding about their pathogenesis.
1,2
The proposed risk factors of neurodegenerative diseases include metal ions [e.g., Zn(II)] and amyloidogenic peptides [e.g., amyloid-b (Ab) and tau for Alzheimer's disease, a-synuclein for Parkinson's disease, and huntingtin for Huntington's disease]. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Toxic aggregates are formed upon aggregation of coordination geometry) have been investigated through multiple physical methods. 8, 9, [22] [23] [24] [25] [26] Such approaches, however, require high concentrations of peptides and metal ions (e.g., high mM) presenting signicant challenge in performing the experiments due to the aggregation-prone properties of amyloidogenic peptides. Unfortunately, detecting the formation of metal-bound amyloidogenic peptides with a straightforward and efficient method (e.g., monitoring a turn-on signal) at a low concentration (ca. nM) has not been reported. Herein, we report a FRET-based probe (A-1; Fig. 1 and Scheme 1), composed of Ab 1-21 graed with a pair of FRET donor and acceptor, for monitoring metal-Ab complexation at a nanomolar range with a turn-on FRET signal. The FRET intensity of A-1 was observed to increase upon binding to Zn(II) (green; Fig. S1 †) . Note that although other metal ions [particularly, Cu(II)] are reported to interact with Ab, 10,24 the use of our probe, A-1, is limited for paramagnetic metal ions, such as Cu(II), because its uores-cence is quenched (Fig. S1 †) . Additionally, the FRET signal of A-1 was changed when (i) Zn(II) binding of A-1 was interfered by the metal chelator, EDTA (ethylenediamine tetraacetic acid), 29 or the compound,
30,31 capable of forming a ternary complex with Zn(II)-Ab; (ii) the probe was aggregated. Moreover, a library of natural products as inhibitors against metal-Ab interaction was screened based on the change in the FRET responses of Zn(II)-treated A-1. 8 out of 145 natural products were identied as effective inhibitors (>80% inhibition) in vitro. Among the 8 molecules, 6 compounds were shown to lower the toxicity associated with Zn(II)-Ab in living cells. Our studies demonstrate the feasibility of developing an efficient tactic to probe metal-amyloidogenic peptide complexation, along with its potential as a screening tool for drug discovery against neurodegenerative diseases.
Results and discussion
Design and preparation of A-1
Our probe, A-1, was designed to have a FRET donor (Trp; l ex ¼ 280 nm, l em ¼ 350 nm) and an acceptor (1-naphthylethylenediamine conjugated to the side chain of an Asp; l ex ¼ 350 nm, l em ¼ 420 nm) for FRET at the C-and N-termini of the Ab 1-21 sequence, respectively (Fig. 1) . Ab was selected as the main framework of A-1 to include the metal binding site of Ab ( Fig. 1b; proposed metal binding residues highlighted in green, e.g., Asp1, Glu3, His6, Asp7, Glu11, His13, and His14). 10, 26, [32] [33] [34] [35] Thus, A-1 itself can interact with metal ions like Ab. When A-1 was treated with Zn(II), the Zn(II)-A-1 complex was formed which was conrmed by mass spectrometry (MS) (Fig. S2 †) . Additionally, the binding affinity [K d ¼ 5.6 (AE0.9) mM] of A-1 (5 mM) for Zn(II) was measured by a uorescence measurement (Fig. S3a †) , similar to the K d values of Zn(II)-Ab obtained using the same method from previous studies.
36-38
Moreover, the progression of peptide aggregation could be observed because A-1 contains a portion of Ab 0 s self-recognition site ( Fig. 1b ; red, Leu17-Phe20). 10, 33, 39 A-1 was synthesized through solid phase peptide synthesis. The detailed synthetic routes are described in Scheme 1 and Experimental section. †
FRET signal of A-1 upon binding to Zn(II)
The presence of Zn(II) induced a signicant turn-on FRET signal of A-1 by >2 fold compared to Zn(II)-free environment (Fig. 2a) . In order to minimize the aggregation of Zn(II)-A-1 (vide infra; Fig. 3 ), along with consideration of our probe's Zn(II) binding property, 250-500 nM of the probe and 100 mM of Zn(II) were used for this study. As shown in Fig. S3b , † the uorescence intensity of A-1 (500 nM) at 420 nm was enhanced upon titration and was saturated at ca. 100 mM of Zn(II). Since FRET occurs when a suitable donor and acceptor pair is in close proximity (1-10 nm) with the parallel orientation of the transition dipoles of the FRET donor and acceptor, 40, 41 an increase in the FRET intensity is indicative of A-1's folding upon Zn(II) binding (Fig. 2a) . The possible conformations of metal-free and Zn(II)-bound A-1 were visualized by modeling with modications of the previously reported structures of metal-free Ab and Zn(II)-bound Ab (PDB: 1AMC 27 and 1ZE9, 28 respectively; Fig. 2b ). Without Zn(II), although the indole ring of the FRET donor and the naphthalene ring of the FRET acceptor are close enough for energy transfer (ca. 2.7 nm), they are not facing each other and shown to be unfavorable to have a dipole-dipole interaction for FRET ( Fig. 2b ; le). Upon interacting with Zn(II), however, the indole and naphthalene rings become closer (ca. 1.1 nm) than those in metal-free A-1 and are facing each other which could be favorable for the dipole-dipole interaction necessary for energy transfer, suggesting that an efficient FRET signal could be observed upon Zn(II) binding to the probe ( Fig. 2b; right) . Additionally, the emission spectrum was blue shied by ca. 25 nm possibly due to an environmental change of the FRET acceptor, naphthylamine, when A-1 was folded with Zn(II) treatment ( Fig. 2a; right) . Note that we cannot rule out that . The structures were generated by modifications of the previously reported structures of metal-free Ab (PDB: 1AMC) 27 and Zn(II)-bound Ab (PDB:1ZE9). 28 The approximate distances between the FRET donor and acceptor were indicated with dashed lines. intermolecular interactions resulted from A-1's propensity to aggregate may induce the FRET.
Aggregation of Zn(II)-bound A-1
In the absence of Zn(II), the FRET signal of A-1 reduced as a function of incubation time (ca. 70% and ca. 85% decrease aer 1 and 3 h incubation, respectively; Fig. S4 †) . This lowered signal may be triggered by the aggregation of A-1 since the probe contains a portion of the self-recognition region of Ab. 10, 33, 39 In contrast, following incubation time, the FRET signal of Zn(II)-treated A-1 decreased (ca. 2% and ca. 18% decrease aer 1 and 3 h incubation, respectively; Fig. 3a ) at a slower rate compared to that of Zn(II)-free A-1 (Fig. S4 †) . This indicates that the aggregation of A-1 could be delayed by the presence of Zn(II), as observed with full-length Ab 40 (Fig. S5 †) . This difference could stem from the disparate conformations of Ab aggregates generated upon the aggregation of metal-Ab, distinct from those of metal-free Ab aggregates.
28,42 Thus, we analyzed the morphologies of Zn(II)-A-1 aggregates upon incubation by transmission electron microscopy (TEM). As depicted in Fig. 3b , small and amorphous aggregates were observed aer 1 h incubation of Zn(II)-added A-1 followed by the detection of larger and more structured aggregates with longer incubation. Based on the variation of the FRET intensity as the probe aggregated, the aggregation process of Zn(II)-A-1 could be divided into three stages: (i) 0-1 h; (ii) 1-3 h; (iii) 3-10 h (Fig. 3a) . Up to 1 h incubation, the FRET signal of Zn(II)-A-1 did not signicantly decrease from the initial measurement. From 1 to 3 h, the FRET intensity of Zn(II)-A-1 dropped drastically and aer 3 h incubation, the FRET responses of Zn(II)-A-1 were shown to be distinguishably reduced slower than those during the 1-3 h incubation period. This could be because Zn(II)-A-1 formed large-sized aggregates, including protobrils and brils, which might restrict its rotation to limit the distance between the FRET donor and acceptor, along with its solubility in aqueous media. Thus, our FRET-based probe, A-1, could monitor the progression of Zn(II)-Ab aggregation, distinct from metal-free Ab aggregation.
Screening inhibitors against Zn(II)-Ab interaction
To evaluate whether Zn(II)-bound A-1 is an effective identica-tion tool for inhibitors against Zn(II)-Ab interaction, alteration of the FRET signal of Zn(II)-A-1 was monitored upon addition of the metal chelator (i.e., EDTA) or the molecule capable of forming a ternary complex with Zn(II)-Ab (i.e., L2-b) (Fig. 4a and Table S1 †) . [29] [30] [31] When EDTA was introduced to Zn(II)-A-1, the FRET intensity was reduced by 83%, compared to the FRET signal of Zn(II)-A-1, and the emission spectrum was red shied back to that observed under Zn(II)-free conditions (Fig. 4a, i ). This suggests that Zn(II) was chelated out from A-1 by EDTA, causing the probe to be unfolded. Furthermore, the treatment of L2-b to Zn(II)-A-1 exhibited a noticeably weaker FRET signal than Zn(II)-A-1 by 82%, but did not present the same emission spectrum as that of Zn(II)-free A-1 (Fig. 4a, ii) . The uorescence behavior of L2-b-added Zn(II)-A-1 implies that a ternary complex [e.g., L2-b-Zn(II)-A-1] could be formed and thus Zn(II) still interacts with A-1, but the distance between the FRET donor and acceptor may not be in close proximity. Note that the emission of Trp was not signicantly changed at ca. 350 nm which was not absorbed by the FRET acceptor upon addition of EDTA and L2-b (Fig. 4a) , indicating that the compounds did not affect the absorption and emission of the FRET donor. Together, our probe, A-1, demonstrates the ability to identify molecules with inhibitory activity towards metal-Ab interaction.
Moving forward, to conrm the screening capability of our FRET-based method to verify molecules as potential inhibitors against metal-Ab interaction, we built up a chemical library containing 145 natural products that do not absorb the FRET signal of Zn(II)-A-1 at ca. 420 nm, similar to EDTA and L2-b (Fig. S6 and Table S1 †). The FRET signal of Zn(II)-A-1 upon addition of natural products was compared to that of Zn(II)-A-1 to calculate % inhibition (Fig. 4b, S7 , and Table S1 †). In our library, (i) 15 molecules could not affect Zn(II) binding to A-1; (ii) 103 compounds showed 0 to 50% inhibition; (iii) 27 natural products induced a signicant decrease in the uorescence of Zn(II)-A-1 by >ca. 50% (Fig. 4b and Table S1 †). Furthermore, among the 27 natural products (>ca. 50% inhibition), 8 compounds (i.e., 9, 37, 61, 71, 73, 84, 106, and 139) demonstrated >80% inhibitory activity against Zn(II)-A-1 interaction. Three compounds (i.e., 61, 71, and 84 out of 8 potent inhibitors; Fig. 4b and Table S1 †) contain both b-amyrin moiety and a,bunsaturated carbonyl groups, previously reported for controlling metal-Ab aggregation. 43 Note that the compounds containing an a,b-unsaturated carbonyl moiety could form a covalent adduct with Ab possibly by reacting with Lys or His. 44, 45 To verify the covalent bond formation between one of (Fig. S8b †) . Thus, our inhibitors containing an a,b-unsaturated carbonyl moiety have the potential to bind A-1. Overall, 
Inuence of inhibitors on toxicity associated with Zn(II) and Zn(II)-Ab
The effect of the 8 natural products that showed >80% inhibition against Zn(II)-A-1 interaction on the toxicity triggered by metalfree and Zn(II)-treated Ab 40 and Ab 42 (two major isoforms of Ab) 6,10 was determined in living cells. We rst examined the toxicity of 10 natural products (i.e., 8 effective natural products: 9, 37, 61, 71, 73, 84, 106, and 139; 2 compounds which may not be able to disrupt Zn(II)-A-1 interaction: 7 and 48) in human neuroblastoma SH-SY5Y (5Y) cells. The tested compounds, except for 37 and 71, were not relatively toxic (>ca. 80% of cell viability at more than 10 mM) in the absence and presence of Zn(II) (Fig. 5a and S9 †) . Employing the relatively less toxic natural products (i.e., 7, 9, 48, 61, 73, 84, 106, and 139) with and without Zn(II), their impact on the toxicity induced by pre-incubated Ab 40 and Ab 42 with and without Zn(II) for 1 h at room temperature was analyzed. The natural products could not ameliorate the toxicity induced by metal-free Ab (Fig. S10 †) . On the other hand, as depicted in Fig. 5b (purple) , cell survival was improved by 6 natural products, determined as effective inhibitors against metal-A-1 interaction, even with the species of Zn(II)-Ab. As expected, the compounds, 7 and 48, shown to hinder Zn(II) binding to Ab by less than ca. 5% (Fig. 4b and Table S1 †), were not able to mitigate the toxicity induced by both metal-free and Zn(II)-associated Ab ( Fig. 5b and S10 ; † gray). Thus, our FRET-based method employing A-1 demonstrates its practical utility to determine molecules that can affect metal-Ab interaction and, as a result, alleviate metal-Ab-linked cytotoxicity.
Conclusions
Since metal ions and amyloidogenic peptides (e.g., Ab) can interact with each other and induce neurotoxicity, our understanding of such complexation is important to reveal their effects in the pathogenesis of neurodegenerative diseases. In order to verify the feasibility of monitoring metal-amyloidogenic peptide interactions, we employed Ab as an example of amyloidogenic peptides to develop a FRET-based probe, A-1, to detect the metal binding of Ab and the progression of metal-Ab aggregation effectively and efficiently. Upon addition of Zn(II), the FRET signal of A-1 was signicantly increased due to the folding of our probe. In addition, when the probe aggregated with Zn(II), its uorescent response was altered in a distinct manner from that of metal-free case. Furthermore, by utilizing our FRET-based probe to screen a chemical library (total 145 compounds), we identied 6 natural products capable of signicantly modulating metal-Ab interaction (>80% inhibition) in vitro and diminishing cytotoxicity associated with Zn(II)-Ab in living cells. Our overall studies illustrate the development of a strategy to monitor metal-Ab interaction and its applicability towards searching potent inhibitors against metal-Ab interaction. In the near future, for biological applications, new and optimized probes will be developed to monitor the interaction between Ab and Zn(II) or other metal ions, including Cu(II), showing more sensitive uorescent responses with lower energy proles for excitation and emission (e.g., near-infrared region). Applying our tactic to other amyloidogenic peptides, their interactions with metal ions could be, and the inhibitors against metal-amyloidogenic peptide interaction could be identied.
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